Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioVersys AG ( (CH:BIOV) ) is now available.
BioVersys AG has reported that Phase 1 single- and multiple-ascending dose data for its investigational antibiotic BV100 in healthy volunteers have been published in the Journal of Antimicrobial Agents and Chemotherapy, confirming a dose-proportional pharmacokinetic profile along with favorable safety and tolerability. BV100, an intravenous rifabutin formulation targeting multi-drug resistant Acinetobacter baumannii infections, has already shown a 50% relative reduction in all-cause mortality versus best available therapy in a Phase 2 trial in ventilator-associated bacterial pneumonia.
On the back of these data, BioVersys has begun a global registration Phase 3 trial, RIV-TARGET, in hospital- and ventilator-associated bacterial pneumonia caused by carbapenem-resistant A. baumannii, with first patient dosing imminent and top-line results expected in the second half of 2027. The company will also launch an open-label Phase 2b differentiation study, RIV-CARE, in the first half of 2026 to compare BV100 with current best therapy across multiple regions, a program that could strengthen BV100’s clinical profile and de-risk its regulatory path in a high-mortality, underserved hospital infection market.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG (SIX: BIOV) is a Basel-based, clinical-stage biopharmaceutical company developing novel antibacterial treatments for serious infections caused by multi-drug resistant bacteria. Leveraging its TRIC and Ansamycin Chemistry platforms, it is advancing candidates targeting hospital-acquired Acinetobacter baumannii infections and tuberculosis, including BV100 in Phase 3 and alpibectir in Phase 2 with GSK and academic partners.
Average Trading Volume: 3,189
Technical Sentiment Signal: Sell
Current Market Cap: CHF142.7M
For a thorough assessment of BIOV stock, go to TipRanks’ Stock Analysis page.